Gossamer Bio, Inc.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary hypertension, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an investigational inhaled small-molecule inhibitor being evaluated in PAH. Gossamer jointly develops it with Chiesi, leads global development and potential U.S. commercialization for PAH and PH-ILD, and shares U.S. commercialization activities equally with Chiesi. Chiesi has exclusive rights to commercialize seralutinib outside the United States. Gossamer also has an option agreement with Respira Therapeutics to acquire RT234, an investigational inhaled, as-needed vardenafil formulation for PAH and PH-ILD. Its development activities are focused on foundational manufacturing and device readiness. Gossamer is headquartered in San Diego, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $GOSS in the last 7 days.
No SEC Form 4 filings for $GOSS in the last 30 days.
See all $GOSS insider activity →Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The following is a brief description of the matter voted upon at the special meeting of stockholders of Gossamer Bio, Inc. (the “Company”) held on October 27, 2026 (the “Special Meeting”) and the number of votes cast
Chardan reiterated a Buy rating and $160 price target for Gossamer Bio (GOSS) after its healthcare conference. Dr. Roxana Sulica expressed safety concerns about WINREVAIR but supported seralutinib. Management expects FDA NDA acceptance by early December, triggering a $125M financing tranche. GOSS trades at $9.61 with a $58.75M market cap, facing liquidity pressures.
Chardan Capital maintained a Buy rating on Gossamer Bio with a $160 price target, implying a 1696.7% upside from the Oct 14 close of $8.90. The firm cited strong clinical data for Seralutinib and a significant market opportunity in treating pulmonary arterial hypertension and PH-ILD.
Recent GOSS coverage spans corporate actions, financial news and regulation.
The approved share issuance is likely to dilute existing shareholders and put downward pressure on the stock.
Potential FDA approval could unlock significant funding and reduce dilution risk.
Analyst upgrade and high price target suggest significant upside potential.
The NDA filing and positive analyst coverage could drive significant buying interest in GOSS.
Regaining compliance removes a delisting risk and may support the stock price.
AlphAI scores every news story that mentions GOSS with an AI model for sentiment and relevance, and aggregates insider trades from Gossamer Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The following is a brief description of the matter voted upon at the special meeting of stockholders of Gossamer Bio, Inc. (the “Company”) held on October 27, 2026 (the “Special Meeting”) and the number of votes cast
1 min readChardan reiterated a Buy rating and $160 price target for Gossamer Bio (GOSS) after its healthcare conference. Dr. Roxana Sulica expressed safety concerns about WINREVAIR but supported seralutinib. Management expects FDA NDA acceptance by early December, triggering a $125M financing tranche. GOSS trades at $9.61 with a $58.75M market cap, facing liquidity pressures.
2 min readChardan Capital maintained a Buy rating on Gossamer Bio with a $160 price target, implying a 1696.7% upside from the Oct 14 close of $8.90. The firm cited strong clinical data for Seralutinib and a significant market opportunity in treating pulmonary arterial hypertension and PH-ILD.
1 min readChardan initiated coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and $160 price target, citing potential FDA approval of seralutinib for PAH therapy. The stock is near its 52-week low at $9.28. The company has a market cap of $56.76M and faces an NDA decision in Q4 2026. Chardan estimates $1.3B in 2035 revenue if approved. Gossamer recently submitted an NDA for seralutinib, supported by clinical trial data. Leerink and H.C. Wainwright also issued positive ratings.
2 min readGossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for con
1 min readGossamer Bio submitted an NDA to the FDA for seralutinib to treat pulmonary arterial hypertension. The submission is based on phase 3 PROSERA and phase 2 TORREY study data. The phase 3 trial did not meet its primary endpoint. This is Gossamer's first NDA submission.
2 min readGossamer Bio (GOSS) shares rose 3.7% after-hours after submitting a New Drug Application for seralutinib, a treatment for pulmonary arterial hypertension, to the FDA. The submission is backed by Phase 3 and Phase 2 study data. The FDA will decide whether to accept the application for review later this year.
2 min readGossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“P
2 min readGossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Gossamer Bio Appoints Greg Ciongoli to Board of Directors SAN DIEGO — (BUSINESS WIRE) — September 16, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatmen
2 min readGossamer Bio (GOSS) fell 6.14% to $10.69 after completing a 1-for-80 reverse stock split. The company's shares are now trading on a split-adjusted basis. The stock's 52-week range is $9.10 to $309.60.
1 min read
